Form 4: Bionano Genomics Director Receives Stock Option Grant

Director David L. Barker was granted 9,149 stock options in Bionano Genomics, Inc. as part of standard equity compensation.

Summary

• Director David L. Barker received a grant of 9,149 stock options on May 14, 2026.
• The options have an exercise price of $1.19 per share.
• The options are set to expire on May 13, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of options.

Risks

• The value of the options is dependent on the future market performance of Bionano Genomics common stock.

Future Outlook

The options vest in equal monthly installments over 12 months, with full vesting occurring by the next annual stockholder meeting or upon a Change of Control.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical equity incentive plans for small-cap biotech companies.
• The use of a 12-month vesting period is standard for annual director compensation cycles.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders.

Next Steps

• Vesting of options over the next 12 months.
• Potential exercise of options by the director after vesting.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Trading, Stock Options, Director Compensation